218 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
28076827	27	New diphenylmethane derivatives as peroxisome proliferator-activated receptor alpha/gamma dual agonists endowed with anti-proliferative effects and mitochondrial activity.	Universit£
27591006	24	Discovery of N-(1-(3-(4-phenoxyphenyl)-1,2,4-oxadiazol-5-yl)ethyl)acetamides as novel acetyl-CoA carboxylase 2 (ACC2) inhibitors with peroxisome proliferator-activated receptora/d (PPARa/d) dual agonistic activity.	The University Of Tokyo
27326332	66	Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.	Bristol-Myers Squibb
26974385	11	Synthesis, in vitro evaluation, and molecular modeling investigation of benzenesulfonimide peroxisome proliferator-activated receptorsa antagonists.	Universit£&Quot;G. D'Annunzio&Quot
26819660	82	SAR Exploration Guided by LE and Fsp(3): Discovery of a Selective and Orally Efficacious ROR¿ Inhibitor.	Central Pharmaceutical Research Institute
27020685	4	Synthetic approaches to the 2014 new drugs.	Pfizer
26731300	3	Amorfrutin C Induces Apoptosis and Inhibits Proliferation in Colon Cancer Cells through Targeting Mitochondria.	Max Planck Institute For Molecular Genetics
26595749	77	N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor¿ Modulators.	Goethe-University Frankfurt
26774923	26	Design, synthesis, and biological evaluation of novel thiazolidinediones as PPAR¿/FFAR1 dual agonists.	Suez Canal University
26707398	2	Characterization of isobutylhydroxyamides with NGF-potentiating activity from Zanthoxylum bungeanum.	Northwest A & F University
26226490	23	Novel Oxazolidinone-Based Peroxisome Proliferator Activated Receptor Agonists: Molecular Modeling, Synthesis, and Biological Evaluation.	Iqm-Csic
25982078	13	Design, synthesis, and biological evaluation of a series of alkoxy-3-indolylacetic acids as peroxisome proliferator-activated receptor¿/d agonists.	Sookmyung Women'S University
25583100	107	Anthranilic acid derivatives as nuclear receptor modulators--development of novel PPAR selective and dual PPAR/FXR ligands.	Goethe-University Frankfurt
25686852	191	Synthesis and biological evaluation of novel pyrrolidine acid analogs as potent dual PPARa/¿ agonists.	Bristol-Myers Squibb Research And Development (R & D)
25497132	34	Design, synthesis and biological evaluation of a class of bioisosteric oximes of the novel dual peroxisome proliferator-activated receptora/¿ ligand LT175.	Universit£
25037914	76	Identification of pirinixic acid derivatives bearing a 2-aminothiazole moiety combines dual PPARa/¿ activation and dual 5-LO/mPGES-1 inhibition.	Goethe-University Frankfurt
25022880	24	Molecular determinants for improved activity at PPARa: structure-activity relationship of pirinixic acid derivatives, docking study and site-directed mutagenesis of PPARa.	Goethe-University Frankfurt
24881566	140	Identification of diarylsulfonamides as agonists of the free fatty acid receptor 4 (FFA4/GPR120).	Glaxosmithkline
24856059	7	trans-Caryophyllene is a natural agonistic ligand for peroxisome proliferator-activated receptor-a.	Korea University
25491112	19	Biological evaluation and structural insights for design of subtype-selective peroxisome proliferator activated receptor-a (PPAR-a) agonists.	National Institute Of Pharmaceutical Education And Research (Niper)
25462281	17	Structural development studies of PPARs ligands based on tyrosine scaffold.	Universit£&Quot;G. D'Annunzio&Quot
25305688	41	Identification of the first inverse agonist of retinoid-related orphan receptor (ROR) with dual selectivity for RORß and ROR¿t.	Phenex Pharmaceuticals
25255039	45	Extending the structure-activity relationship of anthranilic acid derivatives as farnesoid X receptor modulators: development of a highly potent partial farnesoid X receptor agonist.	Goethe-University Frankfurt
24821375	5	The dipeptide H-Trp-Glu-OH (WE) shows agonistic activity to peroxisome proliferator-activated protein-a and reduces hepatic lipid accumulation in lipid-loaded H4IIE cells.	Korea University
24745969	36	Identification of the first potent, selective and bioavailable PPARa antagonist.	Inception Sciences
9836620	94	N-(2-Benzoylphenyl)-L-tyrosine PPARgamma agonists. 1. Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents.	Glaxo Wellcome Research And Development
23286787	18	Structural characterization of amorfrutins bound to the peroxisome proliferator-activated receptor¿.	Helmholtz Centre For Infection Research
23265844	18	The discovery of novel isoflavone pan peroxisome proliferator-activated receptor agonists.	The University Of Sydney
23265881	49	Design, synthesis, and evaluation of imidazo[4,5-c]pyridin-4-one derivatives with dual activity at angiotensin II type 1 receptor and peroxisome proliferator-activated receptor-¿.	Pfizer
24900572	54	Discovery of HSD-621 as a Potential Agent for the Treatment of Type 2 Diabetes.	Pfizer
23171045	38	New 2-(aryloxy)-3-phenylpropanoic acids as peroxisome proliferator-activated receptora/¿ dual agonists able to upregulate mitochondrial carnitine shuttle system gene expression.	Universit�
21414782	178	Phenoxyacetic acids as PPARd partial agonists: synthesis, optimization, and in vivo efficacy.	Glaxosmithkline
20128594	51	Identification and characterization of 4-chloro-N-(2-{[5-trifluoromethyl)-2-pyridyl]sulfonyl}ethyl)benzamide (GSK3787), a selective and irreversible peroxisome proliferator-activated receptor delta (PPARdelta) antagonist.	Glaxosmithkline
23102891	34	Synthesis and structure-activity relationships of fibrate-based analogues inside PPARs.	Universit£
23084275	48	Design, synthesis and evaluation of novel zwitterionic compounds as PPARa/¿ dual agonists (1).	Daiichi Sankyo
22081932	32	Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.	Istituto Tumori&Quot;Giovanni Paolo Ii&Quot
23130964	25	Design and synthesis of dual modulators of soluble epoxide hydrolase and peroxisome proliferator-activated receptors.	Zafes/Liff/Osf Goethe-University Frankfurt
23031596	21	Diarylheptanoid glycosides from Tacca plantaginea and their effects on NF-¿B activation and PPAR transcriptional activity.	Chungnam National University
23022278	14	Design, synthesis and in vitro evaluation of a series ofa-substituted phenylpropanoic acid PPAR¿ agonists to further investigate the stereochemistry-activity relationship.	Okayama University
23137448	16	Fibrate-derived N-(methylsulfonyl)amides with antagonistic properties on PPARa.	Universit£
21800856	50	Lignan derivatives from Krameria lappacea roots inhibit acute inflammation in vivo and pro-inflammatory mediators in vitro.	University Of Innsbruck
22939697	4	Synthesis, radiolabeling and initial in vivo evaluation of [(11)C]KSM-01 for imaging PPAR-a receptors.	Washington University
22260081	12	Targeting peroxisome proliferator-activated receptors (PPARs): development of modulators.	Universit£
22582973	21	Integrated virtual screening for the identification of novel and selective peroxisome proliferator-activated receptor (PPAR) scaffolds.	Trinity College
22564380	624	Activity landscape modeling of PPAR ligands with dual-activity difference maps.	Universidad Nacional Aut£Noma De M£Xico
22534184	87	Discovery, design and synthesis of Y-shaped peroxisome proliferator-activated receptord agonists as potent anti-obesity agents in vivo.	Seoul National University
22579420	45	Total synthesis and dual PPARa/¿ agonist effects of amorphastilbol and its synthetic derivatives.	Korea Institute Of Science And Technology
24936232	16	Discovery of Potent Dual PPARa Agonists/CB1 Ligands.	TBA
22503460	37	Structure-activity relationships and key structural feature of pyridyloxybenzene-acylsulfonamides as new, potent, and selective peroxisome proliferator-activated receptor (PPAR)¿ Agonists.	Takeda Pharmaceutical
22381047	30	Anti-inflammatory and PPAR transactivational effects of secondary metabolites from the roots of Asarum sieboldii.	Chungnam National University
21218783	117	Identification of diaryl ether-based ligands for estrogen-related receptora as potential antidiabetic agents.	Johnson & Johnson Pharmaceutical Research And Development
21128600	16	Design, synthesis, and structural analysis of phenylpropanoic acid-type PPAR¿-selective agonists: discovery of reversed stereochemistry-activity relationship.	Okayama University
20299214	20	(S)-3-(4-(2-(5-Methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)-2-(piperazin-1-yl) propanoic acid compounds: synthesis and biological evaluation of dual PPARalpha/gamma agonists.	Institute Of Pharmacology And Toxicology
20138762	5	Acidic elements in histamine H(3) receptor antagonists.	Johann Wolfgang Goethe University
20073471	15	Design, synthesis, and docking studies of novel benzimidazoles for the treatment of metabolic syndrome.	The University Of Mississippi
19817384	2	Phenoxy herbicides and fibrates potently inhibit the human chemosensory receptor subunit T1R3.	Mount Sinai School Of Medicine
18976908	18	Modulation of PPAR receptor subtype selectivity of the ligands: aliphatic chain vs aromatic ring as a spacer between pharmacophore and the lipophilic moiety.	Zydus Research Centre
18826205	61	Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.	Seoul National University
18511276	86	Design, synthesis, and structure-activity relationships of piperidine and dehydropiperidine carboxylic acids as novel, potent dual PPARalpha/gamma agonists.	Bristol-Myers Squibb R & D
18272370	2	Design, synthesis, biological evaluation and docking studies of pterostilbene analogs inside PPARalpha.	Usda-Ars
17062777	32	Comparative metabolism of radiolabeled muraglitazar in animals and humans by quantitative and qualitative metabolite profiling.	Bristol-Myers Squibb
18155554	87	Synthesis and structure-activity relationships of thiadiazole-derivatives as potent and orally active peroxisome proliferator-activated receptors alpha/delta dual agonists.	Johnson & Johnson Pharmaceutical Research And Development
17964792	31	Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.	Nippon Shinyaku
18162399	37	SAR-oriented discovery of peroxisome proliferator-activated receptor pan agonist with a 4-adamantylphenyl group as a hydrophobic tail.	University Of Tokyo
18280733	27	Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.	Nippon Shinyaku
18291645	108	Discovery of azetidinone acids as conformationally-constrained dual PPARalpha/gamma agonists.	Bristol-Myers Squibb Research And Development
18029176	66	Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.	Johnson & Johnson
17560785	12	Design of a partial PPARdelta agonist.	Novo Nordisk
17005393	35	Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.	Eli Lilly
16617018	4	Diphenylmethane skeleton as a multi-template for nuclear receptor ligands: preparation of FXR and PPAR ligands.	University Of Tokyo
16220969	219	Designed multiple ligands. An emerging drug discovery paradigm.	Organon Laboratories
15546740	41	Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis.	Eli Lilly
12951090	57	O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.	Merck Research Laboratories
22341573	39	Synthesis, biological evaluation and molecular investigation of fluorinated peroxisome proliferator-activated receptorsa/¿ dual agonists.	Universit£
22185225	2	Peroxisome proliferator-activated receptors (PPARs) have multiple binding points that accommodate ligands in various conformations: phenylpropanoic acid-type PPAR ligands bind to PPAR in different conformations, depending on the subtype.	The University Of Tokyo
22070604	150	Benzimidazolones: a new class of selective peroxisome proliferator-activated receptor¿ (PPAR¿) modulators.	Merck Research Laboratories
22209730	73	A new class of non-thiazolidinedione, non-carboxylic-acid-based highly selective peroxisome proliferator-activated receptor (PPAR)¿ agonists: design and synthesis of benzylpyrazole acylsulfonamides.	Takeda Pharmaceutical
22197396	57	Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor¿ selective agonists with protein-tyrosine phosphatase 1B inhibition.	Kyoto Pharmaceutical Industries
22133631	76	Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.	Kyorin Pharmaceutical
22051054	18	Synthesis, molecular modeling studies and biological evaluation of fluorine substituted analogs of GW 501516.	University Of Oslo
21855333	2	Ursolic acid is a PPAR-a agonist that regulates hepatic lipid metabolism.	Korea University
21889235	13	Discovery of gemfibrozil analogues that activate PPARa and enhance the expression of gene CPT1A involved in fatty acids catabolism.	Universit£
21514830	39	Peroxisome proliferator-activated receptor agonists with phenethylphenylphthalimide skeleton derived from thalidomide-related liver X receptor antagonists: relationship between absolute configuration and subtype selectivity.	The University Of Tokyo
21450468	22	Revisiting glitazars: thiophene substituted oxazole containinga-ethoxy phenylpropanoic acid derivatives as highly potent PPARa/¿ dual agonists devoid of adverse effects in rodents.	Zydus Research Centre
21742490	8	Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARa antagonists.	Universit£
21344906	54	Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry.	The University Of Tokyo
21530275	42	Structure-based design, synthesis, and nonalcoholic steatohepatitis (NASH)-preventive effect of phenylpropanoic acid peroxisome proliferator-activated receptor (PPAR)a-selective agonists.	Okayama University
21515063	60	Biological evaluation of novel benzisoxazole derivatives as PPARd agonists.	Nippon Chemiphar
21377875	19	Synthesis and pharmacological evaluation of novel benzoylazole-based PPARa/κ activators.	Dainippon Sumitomo Pharma
21211969	42	Sodium [2'-[(cyclopropanecarbonyl-ethyl-amino)-methyl]-4'-(6-ethoxy-pyridin-3-yl)-6-methoxy-biphenyl-3-yl]-acetate (AM432): a potent, selective prostaglandin D2 receptor antagonist.	Amira Pharmaceuticals
21094606	24	Discovery of isoindoline and tetrahydroisoquinoline derivatives as potent, selective PPARd agonists.	Astrazeneca R&D Charnwood
21130649	11	Development of a new class of benzoylpyrrole-based PPARa/¿ activators.	Dainippon Sumitomo Pharma
21112784	15	Synthesis of a novel human PPARd selective agonist and its stimulatory effect on oligodendrocyte differentiation.	Nippon Chemiphar
21215640	21	Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists.	Zydus Research Centre
21074432	25	Selective peroxisome proliferator-activated receptord isosteric selenium agonists as potent anti-atherogenic agents in vivo.	Seoul National University
20843696	12	Improvement of water-solubility of biarylcarboxylic acid peroxisome proliferator-activated receptor (PPAR)d-selective partial agonists by disruption of molecular planarity/symmetry.	The University Of Tokyo
20638278	145	Synthesis and pharmacological validation of a novel series of non-steroidal FXR agonists.	Phenex Pharmaceuticals
20452212	26	Glycine amides as PPARalpha agonists.	Bayer-Schering Pharma
20356736	48	Synthesis and structure-activity relationships of 2-aryl-4-oxazolylmethoxy benzylglycines and 2-aryl-4-thiazolylmethoxy benzylglycines as novel, potent PPARalpha selective activators- PPARalpha and PPARgamma selectivity modulation.	Bristol-Myers Squibb R & D
20307981	16	Rational design of a pirinixic acid derivative that acts as subtype-selective PPARgamma modulator.	Goethe-University Frankfurt
20218621	131	Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).	Bristol-Myers Squibb
19928766	425	Novel bisaryl substituted thiazoles and oxazoles as highly potent and selective peroxisome proliferator-activated receptor delta agonists.	The Genomics Institute Of The Novartis Research Foundation
19853439	21	Novel biphenylcarboxylic acid peroxisome proliferator-activated receptor (PPAR) delta selective antagonists.	The University Of Tokyo
20022492	29	Design and synthesis of novel bis-oximinoalkanoic acids as potent PPARalpha agonists.	Zydus Research Centre
20079636	78	Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.	Glaxosmithkline
19807106	11	7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.	The University Of Sydney
19791744	23	Synthesis and biological evaluation of 2-heteroarylthioalkanoic acid analogues of clofibric acid as peroxisome proliferator-activated receptor alpha agonists.	Universit£
19775169	41	New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function.	Universit£
19556125	42	Discovery of a novel class of 2-mercaptohexanoic acid derivatives as highly active PPARalpha agonists.	Goethe-University Frankfurt
19719236	23	Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree of unsaturation.	Wake Forest University
19376700	21	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations.	Umr Gicc
19530681	79	Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.	Merck Research Laboratories
19507861	18	Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma a	Merck Research Laboratories
19379014	2	An innovative method to study target protein-drug interactions by mass spectrometry.	Martin-Luther-UniversitäT Halle-Wittenberg
19349176	137	Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.	F. Hoffmann-La Roche
19301897	63	Design and structural analysis of novel pharmacophores for potent and selective peroxisome proliferator-activated receptor gamma agonists.	National Health Research Institutes
19275963	26	Selective, potent PPARgamma agonists with cyclopentenone core structure.	Universidade De Vigo
19201606	86	Design, synthesis and structure-activity relationships of azole acids as novel, potent dual PPAR alpha/gamma agonists.	Bristol-Myers Squibb Research And Development
18947994	102	The discovery of equipotent PPARalpha/gamma dual activators.	Glaxosmithkline
18835719	42	Synthesis, biological evaluation, and molecular modeling investigation of chiral 2-(4-chloro-phenoxy)-3-phenyl-propanoic acid derivatives with PPARalpha and PPARgamma agonist activity.	Università
18821746	10	Discovery of novel PPAR ligands by a virtual screening approach based on pharmacophore modeling, 3D shape, and electrostatic similarity screening.	University Of Innsbruck
18805005	8	Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent.	Zydus Research Centre
18771917	68	Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists.	Yuhan Research Institute
18701276	97	Highly functionalized 7-azaindoles as selective PPAR gamma modulators.	Merck Research Laboratories
18662876	45	Improvement of the transactivation activity of phenylpropanoic acid-type peroxisome proliferator-activated receptor pan agonists: effect of introduction of fluorine at the linker part.	The University Of Tokyo
18625559	16	Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists.	Zydus Research Centre
18329751	40	Synthesis and evaluation of a series of benzopyran derivatives as PPAR alpha/gamma agonists.	Graduate School Of The Chinese Academy Of Sciences
18321611	64	CoMFA analysis of dual/multiple PPAR activators.	National Institute Of Pharmaceutical Education And Research
18255290	28	4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation.	Spot-Ea3857
18060776	100	Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.	Glaxosmithkline
18029178	188	Design and synthesis of novel and potent amide linked PPARgamma/delta dual agonists.	Eli Lilly
17601734	102	Indanylacetic acids as PPAR-delta activator insulin sensitizers.	Bayer Research Center
17553681	50	Novel selective PPARdelta agonists: optimization of activity by modification of alkynylallylic moiety.	Re&D Vufb
17553678	97	Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.	Kowa
17532641	57	Design, synthesis, and evaluation of potent, structurally novel peroxisome proliferator-activated receptor (PPAR) delta-selective agonists.	University Of Tokyo
17524643	14	Phenylpropanoic acid derivatives bearing a benzothiazole ring as PPARdelta-selective agonists.	Nagoya City University
17524639	73	Discovery of para-alkylthiophenoxyacetic acids as a novel series of potent and selective PPARdelta agonists.	Johnson And Johnson Pharmaceutical Research And Development
17512197	101	Synthesis and SAR of selective benzothiophene, benzofuran, and indole-based peroxisome proliferator-activated receptor delta agonists.	Pfizer
17507225	34	Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARalpha/gamma dual agonists.	Seoul National University
17498950	69	Discovery of highly potent and selective benzyloxybenzyl-based peroxisome proliferator-activator receptor (PPAR) delta agonists.	Pfizer
17379517	45	Design of potent PPARalpha agonists.	Novo Nordisk
17343371	27	Identification and synthesis of a novel selective partial PPARdelta agonist with full efficacy on lipid metabolism in vitro and in vivo.	Novo Nordisk
17292606	91	Discovery of tertiary aminoacids as dual PPARalpha/gamma agonists-I.	Bristol-Myers Squibb Pharmaceutical Research Institute
17228882	9	Novel sulfamide analogs of oleoylethanolamide showing in vivo satiety inducing actions and PPARalpha activation.	Instituto De QuíMica MéDica
17157013	74	Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.	Bayer Pharmaceuticals
17129725	90	Design and synthesis of a novel class of dual PPARgamma/delta agonists.	Eli Lilly
17034149	22	Structural basis for the structure-activity relationships of peroxisome proliferator-activated receptor agonists.	National Health Research Institutes
17005394	49	Synthesis and evaluation of aminomethyl dihydrocinnamates as a new class of PPAR ligands.	Eli Lilly
16979341	59	Pyridine-2-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.	Pfizer
16973358	113	Pyridine-3-propanoic acids: Discovery of dual PPARalpha/gamma agonists as antidiabetic agents.	Pfizer
16970391	88	Design and synthesis of dual peroxisome proliferator-activated receptors gamma and delta agonists as novel euglycemic agents with a reduced weight gain profile.	Eli Lilly
16854085	11	Indenone derivatives: a novel template for peroxisome proliferator-activated receptor gamma (PPARgamma) agonists.	Korea Research Institute Of Chemical Technology
16797985	26	Studies towards the conception of new selective PPARbeta/delta ligands.	Université
16750626	51	3,4,5-Trisubstituted isoxazoles as novel PPARdelta agonists: Part 1.	The Genomics Institute Of The Novartis Research Foundation
16737814	112	Structure-based design of indole propionic acids as novel PPARalpha/gamma co-agonists.	F. Hoffmann-La Roche
16546385	81	1,3,5-Trisubstituted aryls as highly selective PPARdelta agonists.	The Genomics Institute Of The Novartis Research Foundation
16529931	139	SAR studies: designing potent and selective LXR agonists.	Merck Research Laboratories
16451087	41	Indol-1-yl acetic acids as peroxisome proliferator-activated receptor agonists: design, synthesis, structural biology, and molecular docking studies.	National Health Research Institutes
16384704	86	Design and synthesis of potent and subtype-selective PPARalpha agonists.	Merck Research Laboratories
16366601	82	Novel indole-based peroxisome proliferator-activated receptor agonists: design, SAR, structural biology, and biological activities.	National Health Research Institutes
16275080	174	Substituted indanylacetic acids as PPAR-alpha-gamma activators.	Bayer Research Center
16275077	27	Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.	University Of Tokyo
16153845	81	Synthesis and biological activities of novel aryl indole-2-carboxylic acid analogs as PPARgamma partial agonists.	Merck Research Laboratories
16137885	59	Synthesis of new carbo- and heterocyclic analogues of 8-HETE and evaluation of their activity towards the PPARs.	Cnrs Umr 6052
16107159	106	Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.	Merck Research Laboratories
16107150	39	Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.	Università
15974597	96	Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.	Merck Research Laboratories
15950464	146	(2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents.	Merck Research Laboratories
15801817	32	Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.	Merck Research Laboratories
15771468	19	Design and synthesis of N-[(4-methoxyphenoxy)carbonyl]-N-[[4-[2-(5- methyl-2-phenyl-4-oxazolyl)ethoxy]phenyl]methyl]glycine [Muraglitazar/BMS-298585], a novel peroxisome proliferator-activated receptor alpha/gamma dual agonist with efficacious glucose and lipid-lowering activities.	Bristol-Myers Squibb Pharmaceutical Research Institute
15713415	13	Structure-activity relationships of dimeric PPAR agonists.	Novo Nordisk
15603954	37	Benzoyl 2-methyl indoles as selective PPARgamma modulators.	Merck Research Laboratories
15582409	46	2-Alkoxydihydrocinnamates as PPAR agonists. Activity modulation by the incorporation of phenoxy substituents.	Eli Lilly
15293980	47	Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.	Glaxosmithkline
15177462	38	Design, synthesis, and evaluation of a new class of noncyclic 1,3-dicarbonyl compounds as PPARalpha selective activators.	Research Institute Of Tsinghua University
15163205	94	(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.	Merck Research Laboratories
15115385	68	Design and synthesis of alpha-aryloxy-alpha-methylhydrocinnamic acids: a novel class of dual peroxisome proliferator-activated receptor alpha/gamma agonists.	Eli Lilly
14613314	53	Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.	Eli Lilly
14584939	32	Large dimeric ligands with favorable pharmacokinetic properties and peroxisome proliferator-activated receptor agonist activity in vitro and in vivo.	Novo Nordisk
14505666	99	Aryloxazolidinediones: identification of potent orally active PPAR dual alpha/gamma agonists.	Merck Research Laboratories
12951082	10	Analysis of the critical structural determinant(s) of species-selective peroxisome proliferator-activated receptor alpha (PPAR alpha)-activation by phenylpropanoic acid-type PPAR alpha agonists.	Kyorin Pharmaceutical
12904063	69	Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.	Kyorin Pharmaceutical
12873517	90	5-aryl thiazolidine-2,4-diones: discovery of PPAR dual alpha/gamma agonists as antidiabetic agents.	Merck Research Laboratories
12729668	106	5-Aryl thiazolidine-2,4-diones as selective PPARgamma agonists.	Merck Research Laboratories
12699745	49	Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.	Glaxosmithkline
12672231	18	Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar.	Novo Nordisk
12657263	46	Phenylacetic acid derivatives as hPPAR agonists.	Merck Research Laboratories
12617924	140	Amphipathic 3-phenyl-7-propylbenzisoxazoles; human pPaR gamma, delta and alpha agonists.	Merck Research Laboratories
12482434	52	Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.	Novo Nordisk
12443777	63	Synthesis and pharmacological evaluation of a new class of peroxisome proliferator-activated receptor modulators.	Biovitrum
11831892	46	Novel tricyclic-alpha-alkyloxyphenylpropionic acids: dual PPARalpha/gamma agonists with hypolipidemic and antidiabetic activity.	Novo Nordisk
11814790	8	Enantio-dependent binding and transactivation of optically active phenylpropanoic acid derivatives at human peroxisome proliferator-activated receptor alpha.	Kyorin Pharmaceutical
11738577	19	Design, synthesis and evaluation of substituted phenylpropanoic acid derivatives as peroxisome proliferator-activated receptor (PPAR) activators: novel human PPARalpha-selective activators.	Kyorin Pharmaceutical
11720854	48	Synthesis and biological activity of L-tyrosine-based PPARgamma agonists with reduced molecular weight.	Glaxosmithkline
11677135	21	Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis.	Glaxosmithkline
11527737	70	Identification of a series of oxadiazole-substituted alpha-isopropoxy phenylpropanoic acids with activity on PPARalpha, PPARgamma, and PPARdelta.	Glaxosmithkline
11405642	33	Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl]ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists.	Eli Lilly
11354382	42	Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis.	Glaxosmithkline
10691680	72	The PPARs: from orphan receptors to drug discovery.	Glaxo Wellcome Research & Development
10508427	42	A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.	Glaxo Wellcome Research & Development
10098657	2	(3-substituted benzyl)thiazolidine-2,4-diones as structurally new antihyperglycemic agents.	Kyorin Pharmaceutical
29446942	98	Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR)?/?/? Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.	Inventiva
28539218	25	Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor?/? (PPAR?/?) dual agonists.	The University Of Tokyo
28799755	51	Polypharmacology of N	Sahmyook University
11121615	32	Synthesis and in vitro opioid activity profiles of DALDA analogues.	Clinical Research Institute Of Montreal
10991998	32	Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition.	Wake Forest University
21671327	5	Triptolide directly inhibits dCTP pyrophosphatase.	Yale University
8474008	58	Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.	Virginia Commonwealth University
20373302	5	The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme.	Universitá
19827080	10	A fragment-based approach to probing adenosine recognition sites by using dynamic combinatorial chemistry.	University Of Cambridge
19843080	43	The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.	Pfizer
8461029	21	Characterization of recombinant human serotonin 5HT1A receptors expressed in Chinese hamster ovary cells. [3H]spiperone discriminates between the G-protein-coupled and -uncoupled forms.	University Of Canterbury
8413837	45	[3H]paroxetine binding in rat frontal cortex strongly correlates with [3H]5-HT uptake: effect of administration of various antidepressant treatments.	Boots Pharmaceuticals
8394987	32	Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase.	Cnrs